Viridian Therapeutics (VRDN)
(Delayed Data from NSDQ)
$15.40 USD
+0.82 (5.62%)
Updated May 3, 2024 04:00 PM ET
After-Market: $15.40 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VRDN 15.40 +0.82(5.62%)
Will VRDN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for VRDN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRDN
How Much Upside is Left in Viridian Therapeutics, Inc. (VRDN)? Wall Street Analysts Think 97.81%
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Tops Revenue Estimates
VRDN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Janux Therapeutics, Inc. (JANX) Moves 5.6% Higher: Will This Strength Last?
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Lags Revenue Estimates
Analysts Estimate Viridian Therapeutics, Inc. (VRDN) to Report a Decline in Earnings: What to Look Out for
Other News for VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
Foghorn Therapeutics appoints Humer as Chief Financial Officer
Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME), Arvinas Holding Company (ARVN) and Viridian Therapeutics (VRDN)
Buy Rating Affirmed for Viridian Therapeutics Amidst TED Treatment Market Potential